Advertisement

Anaplastic Diffuse Large B Cell Lymphoma: A Single Center Experience

  • Neha SinghEmail author
  • Ridhi Sood
  • Narendra Agrawal
  • Sunil Pasricha
  • Anurag Mehta
Correspondence

Dear Sir,

The Anaplastic Diffuse Large B cell Lymphoma (A-DLBCL) is an uncommon distinct morphologic variant of DLBCL characterized by large polygonal cells with bizarre pleomorphic nuclei resembling tumor cells of anaplastic large cell lymphoma (ALCL) or even Reed-Sternberg cells of Hodgkin Lymphoma with a cohesive or sinusoidal growth pattern. A-DLBCL can also simulate malignant melanoma or undifferentiated carcinoma [1, 2]. It accounts for 1–3.5% of all newly diagnosed DLBCL cases according to different studies [3]. Diagnosis of A-DLBCL relies primarily on morphology and extensive immunohistochemical work-up in the absence of any single specific marker as the chances of false positive or erroneous diagnosis of A-DLBCL are higher due to close resemblance to other differentials such as ALCL, EBV-Positive DLBCL, ALK-Positive DLBCL and Hodgkin Lymphoma. Cases of A-DLBCL with hallmark cell appearance indistinguishable from common and giant cell-rich patterns of ALCL [4] and case reports...

Notes

Compliance with Ethical Standards

Conflict of interest

The authors state that there is no conflict of interest present.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Gurbuxani S, Anastasi J, Hyjek E (2009) Diffuse large B-cell lymphoma–more than a diffuse collection of large B cells: an entity in search of a meaningful classification. Arch Pathol Lab Med 133:1121–1134Google Scholar
  2. 2.
    Gascoyne RD, Campo E, Jaffe ES, Chan WC et al (2017) Diffuse large B cell lymphoma, NOS. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of hematopoietic and lymphoid tissues, revised 4 edn. International Agency for Research on Cancer (IARC), Lyon, pp P292–P293Google Scholar
  3. 3.
    Diebold J, Anderson JR, Armitage JO, Connors JM, Maclennan KA, Müller-Hermelink HK et al (2002) Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 43(1):97–104CrossRefGoogle Scholar
  4. 4.
    Sakakibara A, Kohno K, Kuroda N, Yorita K, Megahed NA, Eladl AE et al (2018) Anaplastic variant of diffuse large B-cell lymphoma with hallmark cell appearance: two cases highlighting a broad diversity in the diagnostics. Pathol Int 68(4):251–255CrossRefGoogle Scholar
  5. 5.
    Romero-Guadarrama MB, Aguilar-Ayala LE, Ott G, Pérez-Espinosa J (2012) Diffuse large B-cell lymphoma with anaplastic clear cells: a rare variant. Open J Pathol 2:150–154CrossRefGoogle Scholar
  6. 6.
    Tilly H, Gaulard P, Lepage E et al (1997) Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 90:3727–3734Google Scholar
  7. 7.
    Lai R, Medeiros LJ, Dabbagh L, Formenti KS, Coupland RW (2000) Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma. Mod Pathol 13:223–228CrossRefGoogle Scholar
  8. 8.
    Li M, Liu Y, Wang Y et al (2017) Anaplastic variant of diffuse large Bcell lymphoma displays intricate genetic alterations and distinct biological features. Am J Surg Pathol 41:1322–1332CrossRefGoogle Scholar
  9. 9.
    Nakamura S, Shiota M, Nakagawa A et al (1997) Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21:1420–1432CrossRefGoogle Scholar
  10. 10.
    Sarkozy C, Molina T, Ghesquieres H et al (2017) Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica 102:150–159CrossRefGoogle Scholar
  11. 11.
    Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer (IARC), LyonGoogle Scholar
  12. 12.
    Evens AM, Kanakry JA, Sehn LH et al (2015) Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 90:778–783CrossRefGoogle Scholar
  13. 13.
    Mittal M, Puri A, Nangia R, Sachdeva A (2015) Follicular lymphoma transforming into anaplastic diffuse large B-cell lymphoma of oral cavity: a case report with review of literature. J Oral Maxillofac Pathol 19(3):379–384CrossRefGoogle Scholar
  14. 14.
    Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A et al (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715–2724CrossRefGoogle Scholar
  15. 15.
    Slack GW, Steidl C, Sehn LH, Gascoyne RD (2014) CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol 167(5):608–617CrossRefGoogle Scholar
  16. 16.
    Hao X, Wei X, Huang F, Wei Y, Zeng H, Xu L et al (2015) The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. PLoS ONE 10(5):e0126615CrossRefGoogle Scholar
  17. 17.
    Collie AMB, Hill BT, Manilich EA, Smith MR, His ED (2013) CD30 immunohistochemical expression in diffuse large B-cell lymphoma is associated with decreased overall survival and the non-germinal center molecular subtype. Blood 122:4318Google Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Department of Pathology and Lab ServicesRajiv Gandhi Cancer Institute and Research CenterRohiniIndia
  2. 2.Department of Hemato-OncologyRajiv Gandhi Cancer Institute and Research CenterRohiniIndia

Personalised recommendations